Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
13 nov. 2024 06h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
22 oct. 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
01 oct. 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
13 août 2024 06h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
09 août 2024 07h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
08 août 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
18 juin 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h10 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
15 avr. 2024 08h05 HE
|
Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte